
Home / How it is made
How Celivion Lin J is made
From human dermis to a 150 mg freeze-dried powder: the processing steps and their names.
Starting material
hADM starts as dermal tissue of human origin. Screening of the source material covers 10 serological tests, including hepatitis B nucleic-acid testing (HBV-NAT).
Allo-PELT™ low-temperature decellularization
Cells and fatty components are removed from the dermis. Allo-PELT™ (“Preserved ECM at Low Temperature Processed”) is the name of this step: a stepwise low-temperature circulation system intended to retain ECM components during processing. It uses no acetic acid or pepsin.
Checking what was removed
Residual DNA is listed at 40 ng/mg (ELISA) and a measured Triton X-100 surfactant residue of 0.004% (40 mg/kg, HPLC-ELSD, Koptri). Histology by Kmedihub Preclinical Research Center documents decellularization, collagen density and delipidation.
ECM Mix Cage™ particle step
The decellularized matrix is milled, sized and blended into fine particles. ECM Mix Cage™ is the name of this step. The listed mean particle size is of 33.92 μm (D10 3.23 μm, D50 34.42 μm, D90 61.82 μm; Kyungpook National University), and SEM images in which the collagen grain appears parallel, with uniformly arranged layers.
Freeze-dried presentation
The micronized matrix is supplied as a 150 mg freeze-dried powder (“Lin J: hADM Freeze-dried Powder”). Directions for use follow the product label and the official instructions supplied with the product.
What is in the matrix
The extracellular matrix (ECM) is the collection of dermal components that fill the space around skin cells and support the structure of skin tissue, such as collagen, elastin, fibronectin, laminin, tenascin, growth factors and MMPs. These are general ECM components. The values measured for Celivion Lin J are collagen approx. 82.8%, elastin approx. 4.7% and GAGs approx. 0.23% (Kmedihub), with elastin retention of approx. 85.6% relative to native skin.
Quality data
| Check | Reported value | Laboratory |
|---|---|---|
| Composition | collagen approx. 82.8% · elastin approx. 4.7% · GAGs approx. 0.23% | Kmedihub |
| Elastin retention vs native skin | approx. 85.6% | Kmedihub |
| Residual DNA | 40 ng/mg (ELISA) | listed value |
| Surfactant residue (Triton X-100) | 0.004% (40 mg/kg) | Koptri |
| FT-IR P2/P3 | 0.990 (SD 0.023) | Kyungpook National University |
| Mean particle size | 33.92 μm | Kyungpook National University |
| In-vitro cytotoxicity | 94.8% cell viability (ISO 10993-12 extraction) | KTR |
| Serological screening | 10 tests, including HBV-NAT | listed value |
Sources
- Celivion product brochure (EN), p.8–9 (manufacturing process, Allo-PELT™), p.10 (composition), p.12 (surfactant residue), p.13–14 (decellularization), p.16 (FT-IR), p.18–20 (particle size), p.25 (cytotoxicity), p.29–30 (serology).
- Celivion product catalogue (EN): Allo-PELT™ panel, composition table.
- Celivion product detail-page guide (EN/CN): ECM definition, SEM observation, histology panels (Kmedihub).
- Celivion in-clinic binder (EN), p.12–16.